Cover Image
市場調查報告書

美國的經導管栓塞粒子市場

US Market Report for Transcatheter Embolization Particles - MedCore

出版商 iData Research Inc. 商品編碼 360607
出版日期 內容資訊 英文 92 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的經導管栓塞粒子市場 US Market Report for Transcatheter Embolization Particles - MedCore
出版日期: 2016年02月01日 內容資訊: 英文 92 Pages
簡介

經導管栓塞市場,可分成粒子栓塞,線圈栓塞,液體栓塞,血管塞·脫離型球囊4種。

本報告提供美國的經導管栓塞粒子市場相關調查分析,癌症發病率,市場概要等相關的系統性資訊。

第1章 摘要整理

第2章 調查手法

第3章 癌症發病率

  • 簡介
  • 癌症:各類型

第4章 經導管栓塞粒子市場

  • 簡介
  • 市場概要
  • 市場分析與預測
  • 推動因素·阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭分析

簡稱

圖表

目錄
Product Code: iDATA_USTEP16_RPT

The transcatheter embolization market can be segmented into four types of devices: particle embolics, coil embolics, liquid embolics, vascular plugs and detachable balloons. These are all used for embolization procedures. However, as this report focuses on the treatment of tumors and other oncological indications, the Market Analysis and Forecast section of this report will only discusses the particle embolics segment in detail.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY FOR COMPLETE REPORT SUITE

  • 1.1. MARKET OVERVIEW
  • 1.2. COMPETITIVE LANDSCAPE
  • 1.3. MARKET TRENDS
  • 1.4. KEY MARKET DEVELOPMENTS
  • 1.5. INCIDENCE RATES INCLUDED
  • 1.6. PROCEDURE NUMBERS
  • 1.7. MARKETS INCLUDED
  • 1.8. KEY REPORT UPDATES
  • 1.9. VERSION HISTORY

RESEARCH METHODOLOGY

  • 2.1. RESEARCH SCOPE
  • 2.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

CANCER INCIDENCE RATES

  • 3.1. INTRODUCTION
  • 3.2. CANCER BY TYPE
    • 3.2.1. Genital Cancer
    • 3.2.2. Digestive Cancer
    • 3.2.3. Respiratory Cancer
    • 3.2.4. Breast Cancer
    • 3.2.5. Urinary Cancer
    • 3.2.6. Skin Cancer
    • 3.2.7. Lymphoma
    • 3.2.8. Endocrine System Cancer
    • 3.2.9. Leukemia
    • 3.2.10. Oral Cavity/Larynx
    • 3.2.11. Myeloma
    • 3.2.12. Brain/Other Nervous System
    • 3.2.13. Soft Tissue (Non-Heart)
    • 3.2.14. Bones and Joints
    • 3.2.15. Eye and Orbit

TRANSCATHETER EMBOLIZATION PARTICLE MARKET

  • 4.1. INTRODUCTION
    • 4.1.1. Polyvinyl Alcohol Particles
    • 4.1.2. Microspheres
    • 4.1.3. Drug-eluting Particles
    • 4.1.4. Radioactive Particles
    • 4.1.5. General Information
  • 4.2. MARKET OVERVIEW
  • 4.3. MARKET ANALYSIS AND FORECAST
    • 4.3.1. PVA Particle Market
    • 4.3.2. Microsphere Market
    • 4.3.3. Drug-Eluting Particle Market
    • 4.3.4. Radioactive Particle Market
  • 4.4. DRIVERS AND LIMITERS
    • 4.4.1. Market Drivers
    • 4.4.2. Market Limiters
  • 4.5. COMPETITIVE ANALYSIS

ABBREVIATIONS

LIST OF CHARTS

  • Chart 1-1: Interventional Oncology Device Market by Segment, U.S., 2012-2022 (US$M)
  • Chart 1-2: Interventional Oncology Device Market Overview, U.S., 2015 & 2022
  • Chart 3-1: Male Incidence, Genital Cancer, U.S., 2014
  • Chart 3-2: Male Deaths, Genital Cancer, U.S., 2014
  • Chart 3-3: Female Incidence, Genital Cancer, U.S., 2014
  • Chart 3-4: Female Deaths, Genital Cancer, U.S., 2014
  • Chart 3-5: Male Incidence, Digestive Cancer, U.S., 2014
  • Chart 3-6: Male Deaths, Digestive Cancer, U.S., 2014
  • Chart 3-7: Female Incidence, Digestive Cancer, U.S., 2014
  • Chart 3-8: Female Deaths, Digestive Cancer, U.S., 2014
  • Chart 3-9: Male Incidence, Respiratory Cancer, U.S., 2014
  • Chart 3-10: Male Deaths, Respiratory Cancer, U.S., 2014
  • Chart 3-11: Female Incidence, Respiratory Cancer, U.S., 2014
  • Chart 3-12: Female Deaths, Respiratory Cancer, U.S., 2014
  • Chart 3-13: Incidence by Gender, Breast Cancer, U.S., 2014
  • Chart 3-14: Deaths by Gender, Breast Cancer, U.S., 2014
  • Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2014
  • Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2014
  • Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2014
  • Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2014
  • Chart 3-19: Male Incidence, Skin Cancer, U.S., 2014
  • Chart 3-20: Male Deaths, Skin Cancer, U.S., 2014
  • Chart 3-21: Female Incidence, Skin Cancer, U.S., 2014
  • Chart 3-22: Female Deaths, Skin Cancer, U.S., 2014
  • Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2014
  • Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2014
  • Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2014
  • Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2014
  • Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2014
  • Chart 3-28: Male Deaths, Endocrine Cancer, U.S., 2014
  • Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2014
  • Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2014
  • Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2014
  • Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2014
  • Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2014
  • Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2014
  • Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2014
  • Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2014
  • Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2014
  • Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2014
  • Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2014
  • Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2014
  • Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2014
  • Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2014
  • Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2014
  • Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2014
  • Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2014
  • Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2014
  • Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2014
  • Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2014
  • Chart 4-1: Transcatheter Embolization Particle Market by Segment, U.S., 2012-2022
  • Chart 4-2: Transcatheter Embolization Particle Market Breakdown, U.S., 2015
  • Chart 4-3: Transcatheter Embolization Particle Market Breakdown, U.S., 2022
  • Chart 4-4: PVA Particle Market, U.S., 2012-2022
  • Chart 4-5: Microsphere Market, U.S., 2012-2022
  • Chart 4-6: Drug-Eluting Particle Market, U.S., 2012-2022
  • Chart 4-7: Radioactive Particle Market, U.S., 2012-2022
  • Chart 4-8: Leading Competitors, Transcatheter Embolization Particle Market, 2015

LIST OF FIGURES

  • Figure 1-1: Interventional Oncology Device Market Share Ranking by Segment, U.S., 2015
  • Figure 1-2: Companies Research in this Report Suite, U.S., 2015
  • Figure 1-3: Factors Impacting the Interventional Oncology Device Market by Segment, U.S.
  • Figure 1-4: Recent Events in the Interventional Oncology Device Market, U.S., 2012-2015 (1 of 3)
  • Figure 1-5: Recent Events in the Interventional Oncology Device Market, U.S., 2012-2015 (2 of 3)
  • Figure 1-6: Recent Events in the Interventional Oncology Device Market, U.S., 2012-2015 (3 of 3)
  • Figure 1-7: Cancer Incidence Rates Covered, U.S., 2015 (1 of 2)
  • Figure 1-8: Cancer Incidence Rates Covered, U.S., 2015 (2 of 2)
  • Figure 1-9: Interventional Oncology Procedures Covered, U.S., 2015
  • Figure 1-10: Procedural Codes, U.S., 2015
  • Figure 1-11: Interventional Oncology Device Markets Covered, U.S., 2012-2022 (1 of 2)
  • Figure 1-12: Interventional Oncology Device Markets Covered, U.S., 2012-2022 (2 of 2)
  • Figure 1-13: Key Report Updates, U.S., 2016
  • Figure 1-14: Version History
  • Figure 3-1: Genital Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-2: Digestive Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-3: Respiratory Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-4: Breast Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-13: Soft Tissue (Non-Heart) Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 3-15: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2014
  • Figure 4-1: Transcatheter Embolization Device Characteristics
  • Figure 4-2: Transcatheter Embolization Particle Market by Segment, U.S., 2012-2022 (US$M)
  • Figure 4-3: PVA Particle Market, U.S., 2012-2022
  • Figure 4-4: Microsphere Market, U.S., 2012-2022
  • Figure 4-5: Drug-Eluting Particle Market, U.S., 2012-2022
  • Figure 4-6: Radioactive Particle Market, U.S., 2012-2022
  • Figure 4-7: Drivers and Limiters, Embolization Particle Market, U.S., 2015
  • Figure 4-8: Leading Competitors, Transcatheter Embolization Particle Market, 2015
Back to Top